ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway

Chen Yuan Lin, Hung Jen Chen, Cheng Chung Huang, Liang Chuan Lai, Tzu Pin Lu, Guan Chin Tseng, Ting Ting Kuo, Qian Yu Kuok, Jennifer L. Hsu, Shian Ying Sung, Mien Chie Hung, Yuh Pyng Sher

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The transmembrane cell adhesion protein ADAM9 has been implicated in cancer cell migration and lung cancer metastasis to the brain, but the underpinning mechanisms are unclear and clinical support has been lacking. Here, we demonstrate that ADAM9 enhances the ability of tissue plasminogen activator (tPA) to cleave and stimulate the function of the promigratory protein CDCP1 to promote lung metastasis. Blocking this mechanism of cancer cell migration prolonged survival in tumor-bearing mice and cooperated with dexamethasone and dasatinib (a dual Src/Abl kinase inhibitor) treatment to enhance cytotoxic treatment. In clinical specimens, high levels of ADAM9 and CDCP1 correlated with poor prognosis and high risk of mortality in patients with lung cancer. Moreover, ADAM9 levels in brain metastases derived from lung tumors were relatively higher than the levels observed in primary lung tumors. Our results show how ADAM9 regulates lung cancer metastasis to the brain by facilitating the tPA-mediated cleavage of CDCP1, with potential implications to target this network as a strategy to prevent or treat brain metastatic disease.

Original languageEnglish
Pages (from-to)5229-5243
Number of pages15
JournalCancer Research
Volume74
Issue number18
DOIs
Publication statusPublished - Jul 24 2014

Fingerprint

Plasminogen Activators
Lung Neoplasms
Neoplasm Metastasis
Brain
Tissue Plasminogen Activator
Neoplasms
Lung
Cell Movement
src-Family Kinases
Brain Diseases
Cell Adhesion
Dexamethasone
Proteins
Survival
Mortality
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Lin, C. Y., Chen, H. J., Huang, C. C., Lai, L. C., Lu, T. P., Tseng, G. C., ... Sher, Y. P. (2014). ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Research, 74(18), 5229-5243. https://doi.org/10.1158/0008-5472.CAN-13-2995

ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. / Lin, Chen Yuan; Chen, Hung Jen; Huang, Cheng Chung; Lai, Liang Chuan; Lu, Tzu Pin; Tseng, Guan Chin; Kuo, Ting Ting; Kuok, Qian Yu; Hsu, Jennifer L.; Sung, Shian Ying; Hung, Mien Chie; Sher, Yuh Pyng.

In: Cancer Research, Vol. 74, No. 18, 24.07.2014, p. 5229-5243.

Research output: Contribution to journalArticle

Lin, CY, Chen, HJ, Huang, CC, Lai, LC, Lu, TP, Tseng, GC, Kuo, TT, Kuok, QY, Hsu, JL, Sung, SY, Hung, MC & Sher, YP 2014, 'ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway', Cancer Research, vol. 74, no. 18, pp. 5229-5243. https://doi.org/10.1158/0008-5472.CAN-13-2995
Lin, Chen Yuan ; Chen, Hung Jen ; Huang, Cheng Chung ; Lai, Liang Chuan ; Lu, Tzu Pin ; Tseng, Guan Chin ; Kuo, Ting Ting ; Kuok, Qian Yu ; Hsu, Jennifer L. ; Sung, Shian Ying ; Hung, Mien Chie ; Sher, Yuh Pyng. / ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. In: Cancer Research. 2014 ; Vol. 74, No. 18. pp. 5229-5243.
@article{1d1c55739dcb4ec193bb6d0c59d26de5,
title = "ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway",
abstract = "The transmembrane cell adhesion protein ADAM9 has been implicated in cancer cell migration and lung cancer metastasis to the brain, but the underpinning mechanisms are unclear and clinical support has been lacking. Here, we demonstrate that ADAM9 enhances the ability of tissue plasminogen activator (tPA) to cleave and stimulate the function of the promigratory protein CDCP1 to promote lung metastasis. Blocking this mechanism of cancer cell migration prolonged survival in tumor-bearing mice and cooperated with dexamethasone and dasatinib (a dual Src/Abl kinase inhibitor) treatment to enhance cytotoxic treatment. In clinical specimens, high levels of ADAM9 and CDCP1 correlated with poor prognosis and high risk of mortality in patients with lung cancer. Moreover, ADAM9 levels in brain metastases derived from lung tumors were relatively higher than the levels observed in primary lung tumors. Our results show how ADAM9 regulates lung cancer metastasis to the brain by facilitating the tPA-mediated cleavage of CDCP1, with potential implications to target this network as a strategy to prevent or treat brain metastatic disease.",
author = "Lin, {Chen Yuan} and Chen, {Hung Jen} and Huang, {Cheng Chung} and Lai, {Liang Chuan} and Lu, {Tzu Pin} and Tseng, {Guan Chin} and Kuo, {Ting Ting} and Kuok, {Qian Yu} and Hsu, {Jennifer L.} and Sung, {Shian Ying} and Hung, {Mien Chie} and Sher, {Yuh Pyng}",
year = "2014",
month = "7",
day = "24",
doi = "10.1158/0008-5472.CAN-13-2995",
language = "English",
volume = "74",
pages = "5229--5243",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway

AU - Lin, Chen Yuan

AU - Chen, Hung Jen

AU - Huang, Cheng Chung

AU - Lai, Liang Chuan

AU - Lu, Tzu Pin

AU - Tseng, Guan Chin

AU - Kuo, Ting Ting

AU - Kuok, Qian Yu

AU - Hsu, Jennifer L.

AU - Sung, Shian Ying

AU - Hung, Mien Chie

AU - Sher, Yuh Pyng

PY - 2014/7/24

Y1 - 2014/7/24

N2 - The transmembrane cell adhesion protein ADAM9 has been implicated in cancer cell migration and lung cancer metastasis to the brain, but the underpinning mechanisms are unclear and clinical support has been lacking. Here, we demonstrate that ADAM9 enhances the ability of tissue plasminogen activator (tPA) to cleave and stimulate the function of the promigratory protein CDCP1 to promote lung metastasis. Blocking this mechanism of cancer cell migration prolonged survival in tumor-bearing mice and cooperated with dexamethasone and dasatinib (a dual Src/Abl kinase inhibitor) treatment to enhance cytotoxic treatment. In clinical specimens, high levels of ADAM9 and CDCP1 correlated with poor prognosis and high risk of mortality in patients with lung cancer. Moreover, ADAM9 levels in brain metastases derived from lung tumors were relatively higher than the levels observed in primary lung tumors. Our results show how ADAM9 regulates lung cancer metastasis to the brain by facilitating the tPA-mediated cleavage of CDCP1, with potential implications to target this network as a strategy to prevent or treat brain metastatic disease.

AB - The transmembrane cell adhesion protein ADAM9 has been implicated in cancer cell migration and lung cancer metastasis to the brain, but the underpinning mechanisms are unclear and clinical support has been lacking. Here, we demonstrate that ADAM9 enhances the ability of tissue plasminogen activator (tPA) to cleave and stimulate the function of the promigratory protein CDCP1 to promote lung metastasis. Blocking this mechanism of cancer cell migration prolonged survival in tumor-bearing mice and cooperated with dexamethasone and dasatinib (a dual Src/Abl kinase inhibitor) treatment to enhance cytotoxic treatment. In clinical specimens, high levels of ADAM9 and CDCP1 correlated with poor prognosis and high risk of mortality in patients with lung cancer. Moreover, ADAM9 levels in brain metastases derived from lung tumors were relatively higher than the levels observed in primary lung tumors. Our results show how ADAM9 regulates lung cancer metastasis to the brain by facilitating the tPA-mediated cleavage of CDCP1, with potential implications to target this network as a strategy to prevent or treat brain metastatic disease.

UR - http://www.scopus.com/inward/record.url?scp=84907486062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907486062&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-2995

DO - 10.1158/0008-5472.CAN-13-2995

M3 - Article

C2 - 25060522

AN - SCOPUS:84907486062

VL - 74

SP - 5229

EP - 5243

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 18

ER -